Navigation Links
FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer
Date:4/29/2010

SEATTLE, April 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC).  PROVENGE is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers, and is the first in a new therapeutic class known as autologous cellular immunotherapies.

The FDA approval of PROVENGE is a testament to the courage of the patients and researchers who participated in our studies and is the culmination of nearly 15 years of research and development by our dedicated employees," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon.  "The approval of PROVENGE is a significant step towards realizing our mission of transforming the lives of patients with cancer, and it also marks Dendreon's transformation into a commercial enterprise, ready to support the successful launch of the first personalized treatment for cancer."

Dendreon intends to make PROVENGE available through approximately 50 centers, all of which were approved PROVENGE clinical trial sites, and expects to increase capacity over the next year. The increased capacity will be a result of the anticipated licensure of its expanded New Jersey, Atlanta, Georgia and Orange County, Calif. facilities in mid-2011.

"The approval of PROVENGE, th
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September ... and Chief Executive Officer, will provide an update on ... (9:55 a.m., Pacific Daylight Time).   A ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Orthopedic Instrument Industry Report, 2014-2017" report to their ... and rising proportion of reimbursement for medical expenses, the ... with its scale presenting a CAGR of 19.2% during ... three product segments of orthopedic instruments in ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and Markets ... Drug Pipeline Insight 2014" report to their offering. ... US is one of the largest segments of pharmaceuticals industry. ... rate, while the available therapies were unable to meet the ... the market for CNS disorder, especially over the past two ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2
... Scientific Corporation (NYSE: BSX ) announces results ... WATCHMAN® Left Atrial Appendage Closure (LAAC) device.  The data ... by 75 percent in patients with atrial fibrillation who ... Vivek Reddy, M.D., Director of Cardiac Arrhythmia Service at ...
... ECTE ), a company developing its needle-free ... glucose monitoring system and its Prelude® SkinPrep System for ... quarter ended March 31, 2012.  Echo,s Quarterly Report on ... through Echo,s website at www.echotx.com . ...
Cached Medicine Technology:Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy 2Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy 3Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy 4Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy 5Echo Therapeutics Announces First Quarter 2012 Financial Results 2Echo Therapeutics Announces First Quarter 2012 Financial Results 3Echo Therapeutics Announces First Quarter 2012 Financial Results 4Echo Therapeutics Announces First Quarter 2012 Financial Results 5
(Date:9/1/2014)... September 01, 2014 BCC Research ( ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the global ... in 2013 and is expected to reach $38.7 million ... $471.5 million by 2019, which is equivalent to 64.9% ... The receptor-mediated transport (RMT) segment is forecasted to grow ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many web hosting companies. ... is here to announce that JustHost, Bluehost and ... 2014. , JustHost ( http://www.justhost.com/track/seohosts ) provides new ... plan. The company’s approach to hosting is to ... and powerful enough for anyone to use. And ...
(Date:9/1/2014)... 01, 2014 Pastor Thompson is an ordained ... Eagle Village. He is a licensed minister through the Church ... past twenty years in New Mexico, Colorado and North Dakota. ... marriage this year. He also has two beautiful daughters, ... in Pastoral Ministry from Nazarene Bible College, in Colorado Springs ...
(Date:8/31/2014)... 2014 An analysis of 32 studies ... revealed a link between lower levels of Vitamin D ... the August 2014 issue of American Journal ... form of Vitamin D found in blood. , ... D lower than 9 nanograms/milliliter (ng/mL) were twice as ...
(Date:8/31/2014)... GoDaddy, IX Web Hosting and Bluehost are popular ... hosting, which is the method of partitioning a ... which has the appearance and capabilities of running ... compared many professional web hosting suppliers and announced ... hosting suppliers in the global market. , GoDaddy ...
Breaking Medicine News(10 mins):Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4Health News:GoDaddy, IX Web Hosting and Bluehost Are Awarded As Hosting Experts by Top10BestSEOHosting.com 2
... Christine ... Chief Executive Officer, ... Barr Laboratories, Inc., -- In this newly created position, Mundkur has responsibility for ... development, regulatory affairs, operations, quality, and sales and marketing. Under her leadership, ...
... Corporation announces a,call for research papers involving ... device is designed to promote best practice ... of the administration,set when disconnected from the ... of the IV administration line between drug,administrations, ...
... HILL, N.C., March 28 With continuing economic,woes, ... show,return to gain management buy-in. "Use great service ... a downturn," explained a benchmarking,manager in new product ... there is a downturn.", At "Using Quality ...
... Spokesperson,Andrew McDonald said:, "Instead of ... focus on,helping 70,000 UHW-W members win ... better than to have their contracts ... leadership.", For more information, visit ...
... of "Glacial Pace" in Stopping,Post-Claim Rescissions, Failing to ... 27 California,s,Department of Managed Health Care has ... any of 90 cases of illegal rescission found ... a,hearing in the state Senate,s Health Committee., ...
... of Oriental Medicine at Austin in conjunction with the American, ... ... botanical studies., AUSTIN, Texas, March 27 The High Falls ... Great,Barrington, MA, has been awarded a grant from the W.K. Kellogg ...
Cached Medicine News:Health News:Barr Pharmaceuticals, Inc. Executive Bios 2Health News:Barr Pharmaceuticals, Inc. Executive Bios 3Health News:Barr Pharmaceuticals, Inc. Executive Bios 4Health News:Baxa Corporation Launches Call for Research Papers 2Health News:Superior Customer Service Imperative During Economic Downturn 2Health News:Consumer Advocates Call for Governor to Make Good on His Promise to Protect Patients From Illegal Cancellations of Health Insurance 2Health News:Consumer Advocates Call for Governor to Make Good on His Promise to Protect Patients From Illegal Cancellations of Health Insurance 3Health News:Consumer Advocates Call for Governor to Make Good on His Promise to Protect Patients From Illegal Cancellations of Health Insurance 4Health News:Consumer Advocates Call for Governor to Make Good on His Promise to Protect Patients From Illegal Cancellations of Health Insurance 5Health News:Oriental Medicinal Herb Garden Dedication 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: